Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 5/20 | 0.41 |
| ▸ | HTR1B | P28222 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7009272 | 0.90 | TAAR1 (0.49) | HTR1DHTR1BTAAR1CYP1A2LMNA | |
| SCHEMBL7012293 | 0.71 | NISCH (0.42) | LMNATSHRGAA | |
| SCHEMBL7009355 | 0.71 | HTR1D (0.47) | HTR1DHTR1BTAAR1CYP1A2LMNA | |
| SCHEMBL7009936 | 0.70 | HTR1D (0.43) | HTR1DHTR1BTAAR1CYP1A2LMNA | |
| SCHEMBL21519443 | 0.68 | TAAR1 (0.81) | HTR1DHTR1BTAAR1CYP1A2LMNA | |
| SCHEMBL7013543 | 0.68 | TAAR1 (0.46) | HTR1DHTR1BTAAR1CYP1A2LMNA | |
| SCHEMBL7009403 | 0.67 | TAAR1 (0.47) | HTR1DHTR1BTAAR1CYP1A2LMNA | |
| SCHEMBL11597510 | 0.65 | TAAR1 (0.79) | HTR1DHTR1BTAAR1CYP1A2LMNA | |
| SCHEMBL7005260 | 0.65 | TAAR1 (0.58) | HTR1DHTR1BTAAR1CYP1A2LMNA | |
| SCHEMBL21519534 | 0.65 | TAAR1 (0.56) | HTR1DHTR1BTAAR1CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100769-A1 | Cyclic amidine compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-05-29 | — | — | US | claimed |
| EP-1280793-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2003-02-05 | — | — | EP | claimed |
| WO-2001081334-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | claimed |
| US-20030100769-A1 | Cyclic amidine compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-05-29 | — | — | US | disclosed |
| EP-1280793-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001081334-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100769-A1 | Cyclic amidine compounds | CHRM1, CHRM5, CCKAR | HTR1D 251/4885HTR1B 288/4885TAAR1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.